Aurobindo Pharma has informed that the details of securities dematerialized / rematerialized during the quarter ended June 30, 2025, as required under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, have been furnished to all the stock exchanges where the shares of the Company are listed. The letters confirming this from the RTA - KFin Technologies dated July 2, 2025, are enclosed. Further, the certificates of securities which were dematerialized are listed on the Stock Exchanges where earlier issued securities of the Company were listed.
The above information is a part of company’s filings submitted to BSE.
